Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide crossover study in short bowel syndrome with jejunostomy
2015-000825-35Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Jun 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, double-blind trial of liraglutide in short bowel syndrome (SBS) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in ostomy wet weight output. Started Jun 2015; status: terminated.
02
Drugs
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2015-000825-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000825-35.